Breakthrough pain variability has no impact on response to sublingual fentanyl tablets or placebo
Variability in baseline breakthrough pain (BTP) has no impact on the analgesic response to sublingual fentanyl tablets or placebo.
Variability in baseline breakthrough pain (BTP) has no impact on the analgesic response to sublingual fentanyl tablets or placebo.
Milnacipran treatment resulted in improvements in pain and global status regardless of baseline pain severity or fibromyalgia severity.
Duloxetine, pregabalin, and duloxetine + gabapentin were found to be safe and tolerable for the treatment of diabetic peripheral neuropathic pain.
Tanezumab, a monoclonal antibody that inhibits nerve growth factor, is efficacious in treating osteoarthritis pain and may provide greater symptomatic improvement compared with placebo and naproxen.